Patents Examined by Robert C. Hayes
  • Patent number: 11186630
    Abstract: A human antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3 and a complementarity determining region of an L chain consisting of the amino acid sequence as shown in SEQ ID NOs: 4 to 6. The human antibody of the present invention has the activity to specifically bind to transthyretin (TTR) with structural change and the activity to inhibit fibrillization of TTR and is a human antibody suitable for application to human body.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: November 30, 2021
    Assignee: KM BIOLOGICS CO., LTD.
    Inventors: Masaharu Torikai, Akihiko Hosoi, Tomoyo Takeo, Masayo Ueno, Kenji Soejima, Toshihiro Nakashima, Yukio Ando, Hirofumi Jono, Yu Su, Mineyuki Mizuguchi
  • Patent number: 11167038
    Abstract: The present invention relates to compositions and methods for improving the safety of blood-brain barrier receptor-mediated blood-brain barrier transport.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: November 9, 2021
    Assignee: Genentech, Inc.
    Inventors: Ryan Jefferson Watts, Joy Yu Zuchero, Jessica Couch, Mark Dennis
  • Patent number: 11161903
    Abstract: A method of treating cancer comprising and reducing autoimmune side effects in administration of anti-CTLA-4 antibodies. The invention provides methods for low dose immune checkpoint (IC) treatment of metastatic cancer by delivering anti-CTLA-4 and anti-PD-1 antibodies to cancer patients. Methods also provide for IL-2 stimulation for the activation of T cells against tumor cells. The invention further provides methods for daily cyclic high fever response (hyperthermia) during IL-2 therapy. The methods provide treatment of metastatic cancer without unacceptable autoimmune side effects.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: November 2, 2021
    Inventor: Ralf Kleef
  • Patent number: 11149084
    Abstract: The present disclosure relates to antibodies that bind selectively to pathological Tau, including compositions and methods relating to such antibodies, such as for treating tauopathies, neurodegenerative diseases associated with pathological aggregation of Tau.
    Type: Grant
    Filed: February 8, 2021
    Date of Patent: October 19, 2021
    Assignee: APRINOIA THERAPEUTICS LIMITED
    Inventors: Ming-Kuei Jang, Chin-Yin Tai
  • Patent number: 11149250
    Abstract: The present invention provides methods and compositions for the generation of microglial progenitor cells and microglial cells from pluripotent stem cells, such as embryonic stem cells and induced pluripotent stem cells. The present invention also provides cells produced using such methods, and both methods of treatment and methods of drug screening that use such cells. Also provided are various tissue culture media, tissue culture media supplements, and kits useful for the generation of human microglial progenitor cells and human microglial cells.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: October 19, 2021
    Assignee: New York Stem Cell Foundation, Inc.
    Inventors: Panagiotis Douvaras, Scott Noggle, Stephen Chang, Valentina Fossati
  • Patent number: 11147862
    Abstract: The present disclosure relates to compositions and methods for treating or preventing a disease or disorder of immunoprivileged tissue. It is described herein that an immunogenic composition which induces production of memory CD4 T cells allows for the access of a therapeutic antibody to the immunoprivileged tissue.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: October 19, 2021
    Assignee: Yale University
    Inventors: Norifumi Iijima, Akiko Iwasaki
  • Patent number: 11124552
    Abstract: Liposomes containing tau peptides, preferably phosphorylated tau peptides, and conjugates containing tau peptides, preferably phosphorylated tau peptides, conjugated to an immunogenic carrier are described. Pharmaceutical compositions and uses of the liposomes and/or conjugates for treating or preventing a neurodegenerative disease or disorder, such as Alzheimer's Disease, are also described.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: September 21, 2021
    Assignees: AC Immune SA, Janssen Pharmaceuticals, Inc.
    Inventors: Elizabeth Anne Ramsburg, Donata De Marco, Charlotte Sadaka, Jaap Goudsmit, Andreas Muhs, Maria Pihlgren Bosch, Marija Vukicevic Verhille, Nicolas Piot, Saroj Raj Ghimire
  • Patent number: 11125758
    Abstract: Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: September 21, 2021
    Assignees: Yale University, The Regents of the University of California
    Inventors: Catalin S. Buhimschi, Irina Buhimschi, Charles G. Glabe
  • Patent number: 11098362
    Abstract: The invention is directed to methods for early diagnosis, progression and treatment monitoring of Parkinson's disease (PD) and its differentiation from other neurodegenerative diseases by quantifying brain-enriched miRNA in bodily fluids.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: August 24, 2021
    Assignee: DIAMIR, LLC
    Inventors: Samuil R. Umansky, Kira S. Sheinerman, Vladimir G. Tsivinsky
  • Patent number: 11091747
    Abstract: A cyclic polypeptide, derivative or analogue thereof, comprising an amino acid sequence derived from the C-terminus of acetylcholinesterase (ACh E), or a truncation thereof.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: August 17, 2021
    Assignee: NEURO-BIO LTD
    Inventor: Susan Greenfield
  • Patent number: 11079392
    Abstract: Various aspects and embodiments of the present disclosure are directed to methods and compositions (e.g., kits) for the identification of subjects with misfolded proteins in their urine. For example, methods and compositions for determining that a urine sample from a pregnant woman contains or does not contain misfolded are provided. In some embodiments, the presence of misfolded proteins in a urine sample from a pregnant woman is an indication of preeclampsia.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: August 3, 2021
    Assignee: Yale University
    Inventors: Irina Buhimschi, Catalin S. Buhimschi, Michael Choma, Hemant Tagare, Stephan Michael Jonas
  • Patent number: 11078287
    Abstract: The present invention relates to TrkB binding agonists, and to the use of such agonists in the treatment of neurological disorders and other disorders. The present invention also relates to specific TrkB binding agonists comprising CDRs, variable regions, heavy and light chains, and variant sequences thereof.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: August 3, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Tejinder Kaur Bhinder, Chong Ding, Xu Feng, Wenqing Jiang, Alan Peter Lewis, Yingli Ma, Guhan Nagappan, Radha Shah Parmar, Yangsheng Qiu, Liuqing Yang, Qing Zhang, Yanjiao Zhou
  • Patent number: 11053321
    Abstract: Use of an inhibitor of the ErbB2 receptor for treatment or repair of nerves and/or nerve tissues is provided. The inhibitor includes an antibody, in particular, a monoclonal antibody, for example, Herceptin. A medicament for treatment or repair of nerves and/or nerve tissues can be formulated which includes an inhibitor of the ErbB2 receptor. A pharmaceutical kit may include a medicament having an inhibitor of the ErbB2 receptor and dosing instructions for administrating the medicament for treatment or repair of nerves and/or nerve tissues. Also provided are uses of an inhibitor of the ErbB2 receptor for increasing axon regeneration, preventing neuron or glial cell death, and/or stimulating Schwann cell proliferation in a nerve stump.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: July 6, 2021
    Assignee: THE HOSPITAL FOR SICK CHILDREN
    Inventors: James M. Hendry, Eva Placheta, Tessa Gordon, Gregory H. Borschel
  • Patent number: 11028155
    Abstract: Compositions and methods related to antibodies or antibody fragments which are capable of crossing the blood brain barrier are provided.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: June 8, 2021
    Assignee: Nascent Biotech, Inc.
    Inventors: Mark C. Glassy, Rishab K. Gupta
  • Patent number: 11021517
    Abstract: The present invention provides methods for guiding preservation of human neurons or human nerves during surgery by administering a fluorescently-labeled peptide that specifically binds to the human neurons or human nerves. The invention further provides human neuron or nerve targeting molecules comprising fluorescently-labeled peptides that specifically bind to human neurons or human nerves and compositions thereof.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: June 1, 2021
    Assignee: The Regents of the University of California
    Inventors: Quyen T. Nguyen, Mike Whitney, Dina Hingorani, Roger Y. Tsien, Stephen Adams
  • Patent number: 11007176
    Abstract: The present invention relates to a novel use of actin depolymerizing agents, particularly cytochalasins or derivatives thereof for inhibiting or reversing actin polymerization. Therefore, the present invention provides a method for preventing or treating anxiety disorders and/or alleviating the symptoms thereof, comprising administering to a subject in need thereof a therapeutically effective amount of an actin depolymerizing agent or a derivative thereof.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: May 18, 2021
    Assignee: TZU CHI UNIVERSITY
    Inventors: Ingrid Yichun Liu, Hsien-Ting Huang, Chia-Sheng Pai
  • Patent number: 11001608
    Abstract: AT-rich interactive domain-containing protein 5a (Arid5a) inhibitors can include mid-sized peptides (peptides having less than 15 amino acids) that inhibit the activity of Arid5a. The peptides include the sequence of SEQ ID NO: 1. In an embodiment, the Arid5a peptide inhibitors can include a peptide having a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO:3, and SEQ ID NO:4. The Arid5a peptide inhibitors can be useful for experimental investigation and treating a disease or disorder, such as, inflammation, diseases associated with inflammation, cancer, and autoimmune disease.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: May 11, 2021
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hamza Naim Ahmad Hanieh, Abdullah Mossa Alzahrani
  • Patent number: 10989716
    Abstract: The present disclosure relates to methods of diagnosing acute rejection of a cardiac allograft in a subject using genomic expression profiling, proteomic expression profiling, or both on panels of nucleic acid markers and proteomic markers.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: April 27, 2021
    Assignee: The University of British Columbia
    Inventors: Bruce McManus, Raymond Ng, Scott Tebbutt, Janet Wilson-McManus, Zsuzsanna Hollander, Karen Lam, Virginia Chen, Darlene Dai, Casey Shannon, Andrew Ignaszewski, Robert Balshaw, Robert McMaster, Paul Keown
  • Patent number: 10982002
    Abstract: The present disclosure encompasses novel anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotide of the invention for the treatment and/or prevention of NGF related disorders, particularly in for the management of pain.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: April 20, 2021
    Assignee: Zoetis Services LLC
    Inventors: Sebastian C. J. Steiniger, William Dunkle, Catherine Rugg, Steven A. Dunham
  • Patent number: 10966997
    Abstract: The present invention in various aspects and embodiments provides methods for the treatment or prevention of degenerative disc disease or chronic lower back pain.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: April 6, 2021
    Assignee: ECM DIAGNOSTICS, INC.
    Inventors: Ondrej Slaby, Manu Capoor